Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

Allison W KurianKevin C WardPaul H AbrahamseIrina BondarenkoAnn S HamiltonDennis DeapenMonica MorrowJonathan S BerekTimothy P HoferSteven J Katz

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

A testing gap persists for patients with ovarian cancer (34.3% tested v nearly all recommended), whereas adding more genes widened a racial or ethnic gap in VUS results. Most PVs were in 20 breast cancer-associated genes or ovarian cancer-associated genes; testing other genes yielded mostly VUS. Quality improvement should focus on testing indicated patients rather than adding more genes.

Keyphrases

genome wide
bioinformatics analysis
genome wide identification
quality improvement
end stage renal disease
genome wide analysis
gene expression
metabolic syndrome
adipose tissue
skeletal muscle
young adults
peritoneal dialysis
insulin resistance